<unk>  has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behaviour has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies have shown that this is due to<unk>  mimicking the actions of natural GIP at the GIP receptor. However, at the GLP-1 receptor<unk>  shows bias towards cAMP (a messenger associated with regulation of glycogen, sugar and lipid metabolism) generation, rather than β-arrestin recruitment. This combination of preference towards GIP receptor & distinct signaling properties at GLP-1 suggest this biased agonism increases insulin secretion.<unk>  has also been shown to increase levels of adiponectin, an adipokine involved in the regulation of both glucose and lipid metabolism, with a maximum increase of 26% (10 mg dosage) from baseline after 26 weeks.
Tirzepatide
Plecanatide
Oprelvekin
Vosoritide
Lixisenatide
Abaloparatide
Bulevirtide
Eptifibatide